GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL

Share :
Published: 15 Jun 2021
Views: 500
Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlands

Prof Arnon Kater speaks to ecancer in an online interview for EHA 2021 about the primary analysis of the GLOW study.

He explains that this is a phase III study looking at fixed-duration ibrutinib and venetoclax versus chlorambucil plus obinutuzumab for first-line treatment of elderly and unfit patients with chronic lymphocytic leukaemia (CLL).

Prof Kater reports that ibrutinib and venetoclax demonstrated superior progression-free survival and that the safety profile was consistent with what they expected from treating an elderly comorbid population. He also notes an advantage of this treatment is that it is a once-daily oral treatment.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.